Christophe dombu
Stock Analyst at Kepler Capital
(0.12)
# 4,319
Out of 4,408 analysts
185
Total ratings
37.8%
Success rate
-12.6%
Average return
Main Sectors:
Stocks Rated by Christophe dombu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNN Smith & Nephew | Downgraded: Hold | n/a | $30.46 | - | 1 | Jun 4, 2026 | |
| LON: 0QBO Coloplast A/S | Initiated Coverage: Buy | kr 482.00 | $381.11 | +26.47% | 1 | May 20, 2026 | |
| LON: 0QW0 argenx SE | Maintained: Buy | €810.00 | $757.80 | +6.89% | 33 | May 7, 2026 | |
| AMS: LKFT Lakefront Biotherapeutics NV | Maintained: Sell | €23.50 | $25.08 | -6.30% | 19 | May 7, 2026 | |
| LON: SN Smith & Nephew plc | Maintained: Buy | 1,462p | $1,131.00 | +29.27% | 5 | May 6, 2026 | |
| EPA: VIRP Virbac SA | Maintained: Buy | €415.00 | $340.50 | +21.88% | 6 | Apr 17, 2026 | |
| SWX: KURN Kuros Biosciences AG | Maintained: Buy | CHF 38.00 | $20.60 | +84.47% | 9 | Apr 14, 2026 | |
| SWX: BSLN Basilea Pharmaceutica AG | Maintained: Buy | CHF 69.00 → CHF 70.00 | $49.80 | +40.56% | 27 | Apr 13, 2026 | |
| LON: 0HNZ Fagron NV | Maintained: Buy | €27.50 | $24.74 | +11.17% | 2 | Apr 9, 2026 | |
| EPA: MAAT MaaT Pharma SA | Maintained: Buy | €17.00 | $2.93 | +480.20% | 26 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €14.30 | $4.66 | +206.87% | 25 | Mar 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $1.55 | +681.73% | 26 | Mar 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | €0.10 → €0.01 | $0.191 | n/a | 5 | Feb 7, 2025 |
Smith & Nephew
Jun 4, 2026
Downgraded: Hold
Price Target: n/a
Current: $30.46
Upside: -
Coloplast A/S
May 20, 2026
Initiated Coverage: Buy
Price Target: kr 482.00
Current: $381.11
Upside: +26.47%
argenx SE
May 7, 2026
Maintained: Buy
Price Target: €810.00
Current: $757.80
Upside: +6.89%
Lakefront Biotherapeutics NV
May 7, 2026
Maintained: Sell
Price Target: €23.50
Current: $25.08
Upside: -6.30%
Smith & Nephew plc
May 6, 2026
Maintained: Buy
Price Target: 1,462p
Current: $1,131.00
Upside: +29.27%
Virbac SA
Apr 17, 2026
Maintained: Buy
Price Target: €415.00
Current: $340.50
Upside: +21.88%
Kuros Biosciences AG
Apr 14, 2026
Maintained: Buy
Price Target: CHF 38.00
Current: $20.60
Upside: +84.47%
Basilea Pharmaceutica AG
Apr 13, 2026
Maintained: Buy
Price Target: CHF 69.00 → CHF 70.00
Current: $49.80
Upside: +40.56%
Fagron NV
Apr 9, 2026
Maintained: Buy
Price Target: €27.50
Current: $24.74
Upside: +11.17%
MaaT Pharma SA
Mar 31, 2026
Maintained: Buy
Price Target: €17.00
Current: $2.93
Upside: +480.20%
Mar 26, 2026
Maintained: Buy
Price Target: €14.30
Current: $4.66
Upside: +206.87%
Mar 20, 2026
Maintained: Buy
Price Target: $12
Current: $1.55
Upside: +681.73%
Feb 7, 2025
Downgraded: Sell
Price Target: €0.10 → €0.01
Current: $0.191
Upside: n/a